PORTON PHARMA SOLUTIONS LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.98 CNY | +2.10% |
|
+5.14% | -32.49% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,809 | 7,767 | 19,821 | 48,697 | 22,305 | 9,272 | 9,272 | - |
| Enterprise Value (EV) 1 | 4,809 | 7,767 | 19,821 | 48,697 | 22,305 | 13,735 | 9,272 | 9,272 |
| P/E ratio | 34.1 x | 40.9 x | 60.9 x | 92.2 x | 11.1 x | 51.3 x | 20.8 x | 15.3 x |
| Yield | 0.53% | 0.73% | 0.33% | 0.22% | 2.71% | 1.94% | 1.25% | 1.63% |
| Capitalization / Revenue | 4.06 x | 5.01 x | 9.57 x | 15.7 x | 3.17 x | 3.75 x | 2.39 x | 1.94 x |
| EV / Revenue | 4.06 x | 5.01 x | 9.57 x | 15.7 x | 3.17 x | 3.75 x | 2.39 x | 1.94 x |
| EV / EBITDA | 17.3 x | 24.9 x | 41 x | 66.4 x | 8.9 x | 23.4 x | 8.95 x | 7.17 x |
| EV / FCF | - | - | - | - | 16,016,985 x | - | - | - |
| FCF Yield | - | - | - | - | 0% | - | - | - |
| Price to Book | 1.67 x | 2.53 x | 5.84 x | 12.2 x | 3.72 x | 2.37 x | 1.46 x | 1.36 x |
| Nbr of stocks (in thousands) | 542,748 | 542,748 | 542,748 | 544,405 | 546,027 | 546,038 | 546,038 | - |
| Reference price 2 | 8.860 | 14.31 | 36.52 | 89.45 | 40.85 | 16.98 | 16.98 | 16.98 |
| Announcement Date | 2/25/19 | 2/25/20 | 2/24/21 | 2/28/22 | 3/24/23 | 4/26/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,185 | 1,551 | 2,072 | 3,105 | 7,035 | 3,667 | 3,884 | 4,783 |
| EBITDA 1 | 278.6 | 311.8 | 483.9 | 733.8 | 2,507 | 588 | 1,036 | 1,293 |
| EBIT 1 | 154 | 194.7 | 352.2 | 565.6 | 2,265 | 268.9 | 493.6 | 675.3 |
| Operating Margin | 12.99% | 12.55% | 17% | 18.21% | 32.2% | 7.33% | 12.71% | 14.12% |
| Earnings before Tax (EBT) 1 | 132.9 | 193.4 | 363.7 | 548.8 | 2,246 | 246.6 | 489.6 | 669.4 |
| Net income 1 | 124.5 | 185.6 | 324.4 | 523.9 | 2,005 | 266.9 | 445.1 | 605.7 |
| Net margin | 10.51% | 11.96% | 15.66% | 16.87% | 28.51% | 7.28% | 11.46% | 12.66% |
| EPS 2 | 0.2600 | 0.3500 | 0.6000 | 0.9700 | 3.690 | 0.4900 | 0.8157 | 1.110 |
| Free Cash Flow | - | - | - | - | 1,393 | - | - | - |
| FCF margin | - | - | - | - | 19.8% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | 55.56% | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | 69.44% | - | - | - |
| Dividend per Share 2 | 0.0470 | 0.1040 | 0.1210 | 0.1930 | 1.106 | 0.4870 | 0.2120 | 0.2760 |
| Announcement Date | 2/25/19 | 2/25/20 | 2/24/21 | 2/28/22 | 3/24/23 | 4/26/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 713 | - | 1,304 | 1,817 | 3,121 | 1,378 | 960.9 | 698.3 | 630.4 | 653 | 1,118 | 590 | 822 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | 515.7 | 877.2 | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | 28.38% | 28.11% | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | 510.6 | 867.3 | - | - | - | - | - | - | - | - |
| Net income | - | 830.4 | - | 427.7 | 793.1 | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | 23.53% | 25.41% | - | - | - | - | - | - | - | - |
| EPS | - | 1.510 | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/13/21 | 8/19/22 | 10/25/22 | 3/24/23 | 3/24/23 | 4/21/23 | 8/18/23 | 10/27/23 | 4/26/24 | - | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | 1,393 | - | - | - |
| ROE (net income / shareholders' equity) | 5.79% | 6.25% | 10.1% | 14.2% | 40.3% | 4.6% | 6.61% | 8.31% |
| ROA (Net income/ Total Assets) | 3.45% | - | - | 7.98% | 24% | 4.9% | 4.7% | 5.54% |
| Assets 1 | 3,613 | - | - | 6,562 | 8,353 | 9,109 | 9,471 | 10,937 |
| Book Value Per Share 2 | 5.310 | 5.650 | 6.250 | 7.310 | 11.00 | 10.60 | 11.60 | 12.50 |
| Cash Flow per Share 2 | 0.3600 | 0.6500 | 0.9300 | 0.8900 | 4.700 | 1.150 | 1.510 | 1.610 |
| Capex 1 | 154 | 170 | 393 | 770 | 1,172 | 1,128 | 765 | 776 |
| Capex / Sales | 12.96% | 10.98% | 18.97% | 24.8% | 16.66% | 30.74% | 19.69% | 16.21% |
| Announcement Date | 2/25/19 | 2/25/20 | 2/24/21 | 2/28/22 | 3/24/23 | 4/26/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
16.98
CNY
Average target price
28.5
CNY
Spread / Average Target
+67.84%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.49% | 1.28B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 300363 Stock
- Financials Porton Pharma Solutions Ltd.
